Human Health Therapeutics Research Centre
The NRC's Human Health Therapeutics Research Centre works hand in hand with industry to help biotech firms achieve success and save costs. As an R&D partner of choice, the NRC's Human Health Therapeutics Research Centre de‑risks critical steps in the development of biologics, vaccines, and delivery of large molecules to the brain, to help improve the health of Canadians. We add value to collaborators' products and accelerate their progress to market by overcoming challenges in preclinical and early clinical development, expanding product characterization, optimizing bioprocesses and their scale-up, and developing biomarkers.
Follow the NRC
Services and information
Facilities
Research programs
Expertise
Technology licensing
Biologic molecules
Vaccines
- Synthetic archaeosome adjuvants for improved vaccine formulation
- AMVAD adjuvant for mucosal vaccines
- Salmonella vaccine vector
- Adenoviral vectors for vaccines and cancer therapy
- Immunomodulator for asthma treatment
- Vaccine to prevent Moraxella catarrhalis infection
Expression systems and biomanufacturing
Why work with us
Bernard Massie
Director General (acting)
When you work with us, you have many advantages at your fingertips:
- The largest biologics‑dedicated R&D team in Canada
- Expert involvement from target selection to cGMP‑like bioprocesses
- An experienced team with a track record of satisfied biopharma industry clients
- High‑caliber packages of technologies ready to licence
- Integrated resources throughout the NRC offering access to a wide range of capabilities
While we work with firms of all sizes, these resources make us an especially attractive partner for small- and medium‑sized enterprises, who frequently adopt a virtual wet laboratory model and have limited capacity to invest in research and development.
A globally recognized leader in the field of biologics and vaccine development, we offer our collaborators access to a highly qualified research team that can deliver first rate results while maintaining confidentiality. Through R&D services, collaborations, and licences, our clients can access "à la carte" expertise or collaborate with us for co‑development opportunities. We also transfer large molecule assets, bioprocessing solutions and other enabling technologies to our industrial clients to reinforce a strong, prosperous Canadian biomanufacturing sector with global impact.
Contact us
Eileen Raymond, Business Advisor
Telephone: 514-496-6349
Email: Eileen.Raymond@nrc-cnrc.gc.ca
Submit an online request for information about our programs and services.
Related information
Human Health Therapeutics factsheet (PDF, 1.4 MB)
Research publications
- Enhanced anti-metastatic bioactivity of an IGF-TRAP re-engineered to improve physicochemical properties
- Camelid single-domain antibodies raised by DNA immunization are potent inhibitors of EGFR signaling
- Small-molecule allosteric triggers of Clostridium difficile toxin B auto-proteolysis as a therapeutic strategy
- The S-layer protein of a Clostridium difficile SLCT-11 strain displays a complex glycan required for normal cell growth and morphology
- Structure of the LPS O-chain from Fusobacterium nucleatum strain ATCC 23726 containing a novel 5,7-diamino-3,5,7,9-tetradeoxy-l-gluco-non-2-ulosonic acid presumably having the d-glycero-l-gluco configuration
Report a problem or mistake on this page
- Date modified: